Over the past several years, there has been an explosion in our understanding of the pathogenesis of both acute and chronic leukemia, the number of novel agents with unique mechanisms of action, and other new strategies, including immunologic approaches. Researchers at Memorial Sloan Kettering continue to pursue these and other treatment approaches in our clinical trials.
Relying in part on the information that is emerging about the genetic basis of leukemia, investigators are pursuing approaches that can kill tumor cells directly, inhibit the body’s production of substances that promote their growth, or enhance the immune response against leukemic cells.
Here you can find a continually updated listing of Memorial Sloan Kettering’s current clinical trials for adults with leukemia. Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:
- 22-239 AUGMENT-102: A Phase 1 Study of SNDX-5613 with Chemotherapy for Patients with Leukemias That Have Certain Genetic Changes
- 22-306 A Phase 1 Study of Selinexor and Venetoclax with Chemotherapy in Children, Teens, and Young Adults with Acute Leukemia
For clinical trials for children with leukemia, please visit Pediatric Clinical Trials.
You can also visit our Blood & Marrow Stem Cell Transplantation Clinical Trials.
